| Disease | A LONG-TERM, OPEN-LABEL STUDY, THE EFFECTS OF POLICOSANOL (20MG/D) WERE INVESTIGATED IN THE TREATMENT OF TYPE II HYPERCHOLESTEROLEMIA IN PATIENTS WITH HIGH GLOBAL CORONARY RISK. AFTER DIETARY STABILIZATION DURING A 5-WEEK BASELINE PERIOD, 68
PATIENTS TOOK POLICOSANOL 20MG ONCE DAILY WITH THE EVENING MEAL FOR 12 MONTHS. AFTER TREATMENT WITH POLICOSANOL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL(LDL-C) AND TOTAL CHOLESTEROL DECREASED SIGNIFICANTLY(P<0.00001) BY 24.7% AND 15.9% RESPECTIVELY,
AND HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) INCREASED SIGNIFICANTLY (P<0.0001) BY 31.1%. THE RATIOS OF TOTAL CHOLESTEROL TO HDL-C AND LDL-C DECREASED SIGNIFICANTLY(P<0.00001) BY 29.3% AND 37.8%, RESPECTIVELY. THESE EFFECTS CONTINUED TO
TO INCREASE, ALTHOUGH MODERATELY, DURING THE 12-MONTH FOLLOW-UP. AT THE END OF THE STUDY, REDUCTIONS WERE NOTED IN TOTAL CHOLESTEROL(30.0%), LDL-C(44.8%), TOTAL CHOLESTEROL TO HDL-C RATIO(54.1%), AND LDL-C TO HDL-C RATIO(62.7%), WHEREAS HDL-C
INCREASED BY 68.5%. TRIGLYCERIDES, WHICH DECREASED SIGNIFICANTLY FROM 4 UNTIL 12 MONTHS, WERE 21.2% LOWER AT 12 MONTHS THAN AT BASELINE. OF 59 PATIENTS WHO COMPLETED THE STUDY, 56(94.4%) HAD REDUCTIONS IN LDL-C >15% AT STUDY COMPLETION. THE
TREATMENT WAS WELL TOLERATED; NO DRUG-RELATED CLINICAL OR BIOCHEMICAL ADVERSE EFFECTS(AES) WERE DETECTED. RESULTS OF THE PRESENT STUDY SHOW THAT POLICOSANOL 20MG ONCE DAILY FOR 1 YEAR WAS EFFECTIVE AND WELL TOLERATED IN PATIENTS WITH TYPE II
HYPERCHOLESTEROLEMIA AND HIGH GLOBAL CORONARY RISK. |